Dr. Marc Matrana - Cancer Advocacy ...

Dr. Marc Matrana, MD

Claim this profile

Ochsner Medical Center Jefferson

Expert in Lung Cancer
Studies Cancer
26 reported clinical trials
65 drugs studied

About Marc Matrana, MD

Education:

  • Earned an MD from Louisiana State University School of Medicine, New Orleans, in 2007.
  • Completed Residency in Internal Medicine at Ochsner Clinic Foundation in 2010.
  • Completed Fellowship in Hematology/Oncology at Ochsner Clinic Foundation in 2013.

Experience:

  • Assistant Professor of Medicine at the University of Queensland School of Medicine – Ochsner Clinical School.
  • Director of the Alvin J. Blumkin Center for Innovation and Research in Lung Cancer at Ochsner Health.
  • Specializes in lung cancer and thoracic oncology.

Area of expertise

1

Lung Cancer

Global Leader

Marc Matrana, MD has run 13 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV
2

Cancer

Marc Matrana, MD has run 8 trials for Cancer. Some of their research focus areas include:

Stage IV
RET positive
Stage III

Affiliated Hospitals

Image of trial facility.

Ochsner Medical Center Jefferson

Image of trial facility.

Ochsner High Grove

Clinical Trials Marc Matrana, MD is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

More about Marc Matrana, MD

Clinical Trial Related

6 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Marc Matrana, MD has experience with

  • Pembrolizumab
  • Nivolumab
  • Ipilimumab
  • Gemcitabine
  • Gemcitabine Hydrochloride
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Marc Matrana, MD specialize in?

Is Marc Matrana, MD currently recruiting for clinical trials?

Are there any treatments that Marc Matrana, MD has studied deeply?

What is the best way to schedule an appointment with Marc Matrana, MD?

What is the office address of Marc Matrana, MD?

Is there any support for travel costs?